Corporate News - 14 June 2021

BPL celebrates World Blood Donor Day and the essential contribution of its plasma donors in providing critical therapies worldwide

Download PDF

14 June 2021

Bio Products Laboratory (“BPL”), the specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, celebrates World Blood Donor Day (“WBDD”) in recognition of the critical role of donors worldwide in enhancing and saving lives.

BPL, which collects plasma from its donor communities and processes it to manufacture high-quality products, supports the WBDD’s aims for greater global awareness of the need for safe blood and blood products and recognition of the contribution donors make to national health systems.

David Gao, Chief Executive Officer and Vice Chairman, BPL Holdings, commented:

“We join the WHO in thanking blood donors around the world and support this year’s specific focus on promoting the community values of blood donation and its ability to build solidarity, in particular following the impact of Covid-19 on communities across the world.

For BPL, World Blood Donor Day is a reminder of the essential contribution of donors, and we would like to thank everyone who has donated plasma at one of our 26 collection centres in the US, whose contribution we value greatly.”

About Bio Products Laboratory (BPL):

Recognising the power of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com

BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics.

BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors, in 26 centres across the US. BPL Plasma employs over 900 staff, to support the needs of donors and to ensure high-quality plasma collection in all their centres. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follow industry guidelines. BPL Plasma operates plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services and administrative activities. BPL’s plasma derived medicines are commercially available in the UK, USA and 30 plus other countries around the world through our network of local affiliates and distribution partners.

For more information on Therapies:
www.bplgroup.com